GSK has revealed updated results from its phase 2b trial of its antisense drug for hepatitis B virus (HBV) infections, which reveal a sharp decline in the proportion of patients with undetectable ...

Despite numerous treatment advances, chronic hepatitis B virus (HBV) infection remains a largely incurable disease impacting more than 290 million people worldwide. All patients with chronic HBV ...

Hepatitis B virus (HBV) is the leading cause of cirrhosis, hepatocellular carcinoma, and liver-related death globally.1,2 The highest prevalence is found in low-income and middle-income countries ...

Citing data from Cohort 1 in its ELIMINATE-B Phase 1 dose-finding study, Precision (NASDAQ:DTIL) said PBGENE-HBV was found to be safe and well tolerated in the first three participants who ...

PBGENE-HBV was safe and well tolerated at 0.2 mg/kg, with no serious adverse events in cohort 1 of the ELIMINATE-B trial. Two of three participants showed a substantial reduction in HBsAg after ...